Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SIGA smallpox program gets $2.7 million funding
The grant award will be used to fund SIGA and TransTech Pharma’s joint research efforts directed toward the discovery, optimization, and advancement of lead drug candidates for smallpox
The grant award will be used to fund SIGA and TransTech Pharma’s joint research efforts directed toward the discovery, optimization, and advancement of lead drug candidates for smallpox
Insegia is an investigational therapeutic immunotherapy directed at the growth hormone gastrin. This study randomized 383 previously untreated patients with metastatic pancreatic cancer, to receive Insegia plus gemcitabine
4SC will apply its integrated drug discovery platform to develop drug candidates, ready to enter clinical trials, against two specific targets provided by Sanwa Kagaku Kenkyusho (SKK). 4SC
Vanos, which is manufactured by Patheon Inc in Canada, is a patented corticosteroid cream formulation for once or twice daily application which embodies the heritage of Lidex (fluocinonide),
Patients with moderate-to-advanced Parkinson’s disease (PD) experiencing motor complications, who added once-daily Agilect (rasagiline tablets) to their treatment with optimized levodopa, with or without stable doses of other
The objective of this trial is to assess escalating single doses of REN-850 in approximately 45 healthy volunteers. This trial will represent the first step towards establishing the
Reducing the frequency of seizures remains a significant challenge in treating patients with epilepsy. In fact, more than one-third of epilepsy patients continue to experience seizures while taking
In a colorectal cancer model, the inclusion of CA4P in a two-week treatment regime with Avastin extended the time to progression of these tumors to five times treatment
The study data was obtained by applying Ambit’s novel kinase profiling technology to evaluate the specificity of 20 compounds and reveal potential new uses for some. “Kinases play
TheraQuest believes its unique formulation, TQ-1017, slated for phase III clinical trials in 2005, may have significant safety advantages over other formulations currently in development. Tramadol’s pain relieving